Cannabis Ruderalis

O-1057 molecular geometry.svg
  • 3-(5'-cyano-1',1'-dimethylpentyl)-1-(4-N-morpholinobutyryloxy)-Δ8-tetrahydrocannabinol
PubChem CID
Chemical and physical data
Molar mass522.730 g·mol−1
3D model (JSmol)
  • N#CCCCCC(c3cc1OC([C@@H]4C/C=C(\CC4c1c(OC(=O)CCCN2CCOCC2)c3)C)(C)C)(C)C
  • InChI=1S/C32H46N2O4/c1-23-11-12-26-25(20-23)30-27(37-29(35)10-9-15-34-16-18-36-19-17-34)21-24(22-28(30)38-32(26,4)5)31(2,3)13-7-6-8-14-33/h11,21-22,25-26H,6-10,12-13,15-20H2,1-5H3/t25-,26-/m1/s1

O-1057 is an analgesic cannabinoid derivative created by Organix Inc., Newburyport, Massachusetts, for use in scientific research. Unlike most cannabinoids discovered to date, it is water-soluble, which gives it considerable advantages over many related cannabinoids. It has moderate affinity for both CB1 and CB2 receptors, with Ki values of 8.36 nM at CB1 and 7.95 nM at CB2[1]

See also[edit]


  1. ^ Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR (April 2000). "O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties". British Journal of Pharmacology. 129 (8): 1577–84. doi:10.1038/sj.bjp.0703245. PMC 1572002. PMID 10780961.

Leave a Reply